NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding NRX Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 30 | 31 | +1 |
| Shares | 3.99M | 3.73M | −256.9K (−6.4%) |
| Value | $1.84M | $1.76M | −$76.7K (−4.2%) |
New holders (4)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 39,396 | $18.6K | 0.00% |
| Jane Street Group, LLC | 27,685 | $13.1K | 0.00% |
| FMR LLC | 110 | $52 | 0.00% |
| Simplex Trading, LLC | 195 | $0 | 0.00% |
Sold out (3)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| HighPoint Advisor Group LLC | 43,501 | $23.0K |
| HBK Sorce Advisory LLC | 29,230 | $13.4K |
| Bank of America Corp | 72 | $34 |